BioNTech to pay $1.2 billion over vaccine royalties

BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennsylvania over the payment of royalties related to its COVID-19 vaccine,
COVID: BioNTech to pay $1.2 billion over vaccine royalties
German pharmaceutical company BioNTech has agreed to pay a combined sum of more than $1.2 billion to resolve separate disputes over royalty payments related to its COVID-19 vaccine.
BioNTech to pay Covid-19 vaccine settlements in US
The German pharmaceutical company BioNTech announced on Friday that it has reached settlements in the US to resolve a royalties dispute with the US National Institutes of Health (
BioNTech to pay $467M in settlement agreement with University of Pennsylvania
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University of Pennsylvania concerning royalties and other related amounts allegedly owed on sales of the Company’s,
BioNTech to Pay Up to $1.26B in Covid-19 Vaccine Settlements With NIH, Penn
BioNTech has agreed to pay $1.26 billion across two separate settlements with the National Institutes of Health and the University of Pennsylvania tied to royalties for its Covid-19 vaccine. The German developer of RNA vaccines and immunotherapies,
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claims
BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine royalty claims. Read more here.
Daily4h
BioNTech enters settlement with US National Institutes of Health, University of Pennsylvania
Bengaluru: German biotechnology company BioNTech has reached two separate settlement agreements with the U.S. National ...
BioNTech's Big Moves: $1.2 Billion Settlements and a Game-Changing Cancer Bet
Settling royalty disputes and acquiring Biotheus, BioNTech reshapes its future in vaccines and oncology innovation.
BioNTech SE ADR rises Friday, outperforms market
BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.
devdiscourse3h
Breaking Health Updates: FDA, Novartis, and Global Disease Monitoring
Recent health developments include a new injectable cancer drug by Bristol Myers Squibb, a revived lawsuit against Novartis ...
Here are Morgan Stanley’s key oncology catalysts for 2025
Last year, Moderna ( NASDAQ: MRNA) made headlines with its individualized mRNA cancer vaccine mRNA-4157 (V940), developed ...
BioNTech Enters Into Settlements With U.S. Agency, UPenn Over COVID-19 Vaccine Royalties
Concurrently, the company has amended its license agreements to provide for a low single-digit percentage royalty on Net Sales of Licensed Products for 2024 onwards. Currently, BioNTech's stock is ...
BioNTech SE ADR falls Thursday, underperforms market
The ADR's fall snapped a three-day winning streak.
devdiscourse19h
Regulatory Developments in Health: From Cancer Drugs to Vaccine Royalties
Recent developments in health include the FDA approving an injectable version of Opdivo, a revived lawsuit against Novartis ...
South Korea impeaches acting president Han Duck-soo
South Korea's parliament impeached acting President Han Duck-soo on Friday, less than two weeks after suspending President ...